



October 16, 2009



Financial Report First 2 Quarters of Fiscal 2009

(April 1 – September 30, 2009)

Jun-ichi Hoki, President and CEO


Kazuo Takahashi, Director, Administration Div.

Notice Regarding Forward-Looking Statements

This presentation contains statements about the Company's plans, forecasts, strategies, and beliefs related to its future performance. Such forward-looking statements were prepared based on judgments of the Company's management according to information available when this presentation was prepared. Readers are asked not to rely completely on performance forecasts contained herein, and understand that actual results may differ from such forecasts.

Financial results reported herein have not been audited.


First Half Overview




Fiscal 2009-Fisrt 2 Quarters Income Statements

(Unit: million yen, rounded down)	Fiscal 2008 First 2 Quarters Results		Fiscal 2009 First 2 Quarters Results		Year-on-Year Comparison	
Tounded down)	Amount	% of Total	Amount	% of Total	Amount	%
Net sales	15,329		15,846		517	3.4%
Operating income	3,767	24.6%	4,019	25.4%	251	6.7%
Ordinary income	3,827	25.0%	3,959	25.0%	131	3.4%
Net income	2,295	15.0%	2,376	15.0%	80	3.5%
EPS	152.72 yen		153.91 yen			

Fiscal 2009-First 2 Quarters Sales Growth by Major Products



Net Sales per Day for Kit Products






Fiscal 2009-First 2 Quarters Main Points

- Began proposing our surgery management system to customers
- Signed ten new Operamaster contracts and canceled six
 (112 contracts in force at end of term)
- Rollout delays of Operamaster at newly contracted hospitals
- Progress delays in Operamaster contracts
- Four less days of operation in the first half of this fiscal year compared to the same period in the previous year
- Posted new factory's construction costs as cost of sales during the second quarter (as planned)
- Posted foreign exchange loss from U.S. dollar loans to a subsidiary


Forecast for Second Half



Fiscal 2009 Projected Statement of Income

(Unit: million yen, rounded down)	Fiscal 2008 Results		Fiscal 2009 Plans		Year-on-Year Comparison	
	Amount	% of Total	Amount	% of Total	Amount	%
Net sales	31,009		32,600		1,590	105.1%
Operating income	7,501	24.2%	8,590	26.3%	1,088	114.5%
Ordinary income	7,627	24.6%	8,710	26.7%	1,082	114.2%
Net income	3,584	19.3%	5,210	16.0%	1,625	145.3%
EPS	238.47 yen		331.19 yen			

Fiscal 2009 Sales Growth by Major Products





Status of Operamaster Target for Hospitals

Operamaster
Contracts
430,000 operations
(112 hospitals)


Pre-Operamaster 410,000 operations (90 hospitals)


Hospitals with internal agreements

1.34 million operations (347 hospitals)

Operamaster target for Hospitals

Number of operations: about 4 million; Number of hospitals: 1,150





Fiscal 2009-Second Half Key Point

Concluding contracts with new hospitals

Starting of operations at an early stage with contracted hospitals

 Promoting the introduction of surgery management system at Operamaster-contracted hospitals

A key risk factor is the impact from exchange rate fluctuations

Performance Overview



Progress of Operamaster Marketing

Sales: ¥3,365 million (up ¥473 million, or 16.4%)

Number of Contracts:

6 new contracts; 1 cancelled contracts (an increase of 22,300 operations)


(Cumulative total: 10; 6 cancellation)

Pre-Operamaster:

¥933 million (up ¥57 million, or 6.6%)


- Concluded 7 Operamaster contracts out of 97 candidates as of the start of the fiscal year
- Increasing size of contracted hospitals
- Cancellation of contracts with small hospitals

Operamaster-Contracted Hospitals: Breakdown by Size







Sales Breakdown by Hospitals Size of Operamaster-Contracted Hospitals




Number of Operamaster Operations



Sales of Operamaster



Operamaster-Diffusion Rate and Number of Operations






Fiscal 2009-First 2 Quarters Cost and SG&A Expenses Analysis (year-on-year)


Cost of sales ratio: 0.1% year-on-year increase

48.9% (FY2008; First half) → 48.8% (FY2009; First half)

SG&A expenses: Up ¥29 million year-on-year

¥4,065 million (FY2008; First half) → ¥4,094 million (FY2009; First half)





Fiscal 2009-First 2 Quarters Non-Operating Income/Loss and Capital Expenditures

Non-operating income/loss:

- -¥60 million yen (down ¥119 million year-on-year)
 - Loss on valuation of loan to subsidiary: ¥126 million

Capital Expenditures:

¥2,008 million (up ¥873 million year-on-year)

- New EB sterilizer: ¥876 million
- •Indonesia plant: ¥590 million

Depreciation costs:

¥1,252 million (up ¥16 million year-on-year)

- Cost of sales: ¥898 million (up ¥28 million year-on-year)
- SG&A expenses: ¥354 million (down ¥12 million year-on-year)



Indonesia Plant



Completed on September 2009


Total construction costs: Approximately 14 million dollars




HOGY MEDICAL Co., Ltd.

Fiscal 2009 Plans

Fiscal 2009 Sales Growth by Major Products



Fiscal 2009-Second Half Sales Growth by Major Products





Revision of Net Sales

(Unit: million yen, rounded down)		Fiscal 2009 Initial Plans		Fiscal 2009 Revised Plans		Initial Plan Comparison	
		Amount	% of Total	Amount	% of Total	Amount	%
Surgical products		27,667	84.9%	27,574	84.6%	-103	99.6%
	Kit Products	15,220	46.7%	14,370	44.1%	-850	94.4%
	Non-woven fabrics	10,874	33.4%	11,144	34.2%	270	102.5%
	Other non-woven fabrics	1,510	4.6%	2,000	6.1%	490	132.5%
	Steel instruments	73	0.2%	60	0.2%	-13	81.4%
Sterilization products		3,721	11.4%	3,770	11.6%	49	101.3%
Treatment products		262	0.8%	280	0.9%	18	106.9%
Other products		939	2.9%	976	3.0%	36	103.9%
Total		32,600	100.0%	32,600	100.0%	0	100.0%



